Clinical Trial Update: TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for TD-9855 in neurogenic orthostatic hypotension (nOH) completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple System Atrophy with Orthostatic Hypotension
• Neurogenic Orthostatic Hypotension
• Orthostatic Hypotension
• Parkinson Disease
• Pure Autonomic Failure

Drugs mentioned

• TD-9855

Snippet

Sponsor: Theravance Biopharma | Conditions: Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension | Phase 2 | Status: COMPLETED | Results posted: 2022-09-26